NASDAQ:UNCY

Thinking about buying stock in Unicycive Therapeutics, Stratasys, Enovix, Azul SA, or eHealth?

Retrieved on: 
Friday, March 10, 2023
Main Street, Multimedia, Wall Street, Retail

Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.

Key Points: 
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
  • We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

CEO Clip Video Highlights How Unicycive Therapeutics is Working to Improve Quality of Life for Patients Suffering from Kidney Diseases

Retrieved on: 
Wednesday, June 29, 2022
BTV, Kidney, CEO, Television, Video, Pharmaceutical industry, Amusement arcade

Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Business Television (BTV) chats with Shalabh Gupta, M.D., CEO of Unicycive Therapeutics Inc. (NASDQ: UNCY) to learn more about how they are developing life-changing new medicines to treat a variety of kidney diseases with significant unmet medical needs.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Business Television (BTV) chats with Shalabh Gupta, M.D., CEO of Unicycive Therapeutics Inc. (NASDQ: UNCY) to learn more about how they are developing life-changing new medicines to treat a variety of kidney diseases with significant unmet medical needs.
  • If you cannot view the video above, please visit:

Glancy Prongay & Murray LLP Announces Investigation of Unicycive Therapeutics, Inc.

Retrieved on: 
Thursday, April 14, 2022
Legal, Professional Services, Park Avenue, Nasdaq, Company, Helmsley Building, Suite, GPM

Glancy Prongay & Murray LLP (GPM) announces its investigation of Unicycive Therapeutics, Inc. (Nasdaq: UNCY) concerning the Company and its directors and officers possible violations of state laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM) announces its investigation of Unicycive Therapeutics, Inc. (Nasdaq: UNCY) concerning the Company and its directors and officers possible violations of state laws.
  • If you inquire by email please include your mailing address, telephone number, and the number of shares purchased and held.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20220414005898/en/